Halozyme Therapeutics, Inc. (HALO)
Fair bewertetFundamental
70
Kurs
$109.58
Marktkapitalisierung
$12.53B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
West sells self-injection systems such as the SmartDose wearable injector to the same biopharma customers looking to move an infused drug into a patient-administered subcutaneous format.
Alteogen's ALT-B4 hyaluronidase is the only validated alternative to Halozyme's rHuPH20 for converting intravenous biologics to subcutaneous injection, and it has taken licensing deals with Merck, AstraZeneca and Novartis that Halozyme was competing for.
Enable's enFuse on-body injector lets pharmaceutical companies move large-volume intravenous drugs to subcutaneous administration without a hyaluronidase, chasing the same partnerships and the same royalty streams as Halozyme.
Ypsomed supplies pharmaceutical companies with autoinjector and pen platforms for self-administered biologics, the same device business Halozyme bought with Antares Pharma.
SHL Medical designs and manufactures autoinjectors for large pharmaceutical partners, competing directly for the device-development and manufacturing contracts that feed Halozyme's specialty product line.
Amphastar's Amphadase is the bovine hyaluronidase that Halozyme's own 10-K names as the competing product to its marketed drug Hylenex.
Bilanz & Liquidität
Umsatz
$1.66B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$414M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$645M
Gesamtes Eigenkapital
$49M
Gesamtverbindlichkeiten
$2.48B
Current Ratio
2.71
Zinsdeckungsgrad
29.41
Schulden/EBITDA
4.53
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$141.68
Aktueller Kurs
$109.58
Sicherheitsmarge
+22.7%
Innerer-Wert-Spanne
$92.09 - $191.27
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
32.28
ROE
649.2%
P/B-Verhältnis
87.29
P/FCF
15.54
Bruttomarge
82.4%
ROIC
21.1%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
21.1%
WACC
8.4%
ROIC − WACC
+12.7 pp
Der ROIC übersteigt die Kapitalkosten: Das Unternehmen schafft Wert für die Aktionäre.
Fundamentalanalyse-Kriterien
Bestanden (19)
- EPS shows upward trend
- Price CAGR 27.54%
- ROIC 21.1%
- Gross Margin 82.4%
- P/FCF 15.54
- Operating Margin 35.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 180.6%
- Revenue Growth 5Y 39.2%
- Analyst Consensus 81% Buy
- PEG Ratio 1.34
- Earnings Quality (OCF/NI) 1.98
- Share Dilution -4.4%
- Piotroski F-Score 5/9
Nicht bestanden (7)
- P/B Ratio 87.29
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg -20.7%
- Net Margin Trend 24.9% vs 47.3%
Nicht verfügbar (1)
- Dividend Payout NaN%
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director | 62 |
| Mr. Mark Snyder Esq. | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 58 |
| Mr. Darren Snellgrove | Senior VP & CFO | - |
| Mr. Brian Sweeney | Chief Human Resources Officer | 61 |
| Mr. David A. Ramsay MBA | President of Drug Delivery | 60 |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer | - |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer | 61 |
| Mr. Paul Spence | Chief Commercial Officer | 56 |
| Mr. Rhys de Callier | Chief Strategy Officer | - |
| Mr. Chase Coffman Ph.D. | President of Hypercon | - |
Prüfungsrisiko
3
Vorstandsrisiko
1
Vergütungsrisiko
4
Aktionärsrechterisiko
3
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-17
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-08-06
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-09-30
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for HALO, sourced from Markets Gazette.